Home \ Antibodies \ C5aR, Human, mAb S5/1
Catalog # HM2094

C5aR, Human, mAb S5/1

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody S5/1 recognizes the human receptor for C5a (CD88). The C5a receptor- is a seven transmembrane GTP-binding-protein-coupled receptor of 45kDa which binds with high affinity to human anaphylatoxin C5a. Upon C5a binding- G-protein-dependent cellular- responses are initiated such as increased intracellular Ca2+, granule fusion with the cell membrane, enzyme release and oxidative burst suggesting that C5aR is an important mediator of inflammation. The C5a receptor is expressed on a broad range of cell types, including- neutrophils, monocytes/macrophages, dendritic cells, astrocytes and microglia.
Interestingly, C5a receptor signalling has been associated with several inflammatory diseases including rheumatoid arthritis.-
Clone S5/1 was raised against a synthetic peptide comprising the N-terminal domain of the C5aR (Met1-Asn31). The antibody has been shown to inhibit the binding of C5a to its receptor.

Application
Flow cytometry, Frozen sections, Functional studies, Paraffin sections, Western blot

Application Notes
FC: Antibody S5/1 stains the N-terminal domain of CD88. 1x106 leukocytes were incubated with 2 µg of antibody (Ref. 1).
FS: Antibody S5/1 inhibits C5a binding to its receptor at a concentration of 3.3 µM (Ref. 2)
IHC-P: Tissue sections were fixed in 2% paraformaldehyde and pretreated with 5% normal rabbit serum before applying antibody S5/1 (Ref. 3).
W: extracts from smooth muscle cells were separated by SDS-PAGE, the observed band size with S5/1 antibody is 42kDa (Ref. 5).

Use
For immunohistology, flow cytometry and Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of binding of C5a to its receptor dilutions have to be made according to the amounts of C5a to be inhibited.

Positive Control
Whole blood granulocytes

Product type
Monoclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
Immunogen
Synthetic peptide comprising the N-terminal domain of the C5aR (Met1-Asn31)
Isotype
Mouse IgG2a
Species
Human
Cross reactivity
Rabbit – Yes
Alias
Complement component 5a receptor 1, CD88, C5aR, C5a anaphylatoxin receptor.
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease
Infectious diseases, Nephrology
Protocol
Protocol Western Blot
59 kb
Protocol SDS Page
57 kb
Protocol IHC-P
43 kb
Protocol Flow Cytometry
58 kb
Protocol IHC-F
36 kb
CoA-TDS HM1067-HM2099
HM2094-100UG
80 kb
HM2094-20UG
80 kb
Safety Data Sheet
SDS - HM2094-100UG
51 kb
SDS - HM2094-20UG
51 kb

Related products

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Show data entry

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us